{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:38:36Z","timestamp":1772728716977,"version":"3.50.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitor (ICI) combinations extend overall survival (OS) while anti-PD-1\/L1 monotherapy is non-inferior to sorafenib in treatment-na\u00efve, patients with advanced hepatocellular carcinoma (HCC). Clinicogenomic features are posited to influence patient outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The primary objective of this retrospective study was to define the clinical, pathologic, and genomic factors associated with outcomes to ICI therapy in patients with HCC. Patients with histologically confirmed advanced HCC treated with ICI at Memorial Sloan Kettering Cancer Center from 2012 to 2022 were included. Association between clinical, pathological, and genomic characteristics were assessed with univariable and multivariable Cox regression model for progression-free survival (PFS) and OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two-hundred and forty-two patients were treated with ICI-based therapy. Patients were predominantly male (82%) with virally mediated HCC (53%) and Child Pugh A score (70%). Median follow-up was 28 months (0.5-78.4). Median PFS for those treated in 1st line, 2nd line and\u2005\u2265\u20053rd line was 4.9 (range: 2.9-6.2), 3.1 (2.3-4.0), and 2.5 (2.1-4.0) months, respectively. Median OS for those treated in 1st line, 2nd line, and\u2005\u2265\u20053rd line was 16 (11-22), 7.5 (6.4-11), and 6.4 (4.6-26) months, respectively. Poor liver function and performance status associated with worse PFS and OS, while viral hepatitis C was associated with favorable outcome. Genetic alterations were not associated with outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Clinicopathologic factors were the major determinates of outcomes for patients with advanced HCC treated with ICI. Molecular profiling did not aid in stratification of ICI outcomes. Future studies should explore alternative biomarkers such as the level of immune activation or the pretreatment composition of the immune tumor microenvironment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae110","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T05:33:17Z","timestamp":1719552797000},"page":"894-903","source":"Crossref","is-referenced-by-count":5,"title":["Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy"],"prefix":"10.1093","volume":"29","author":[{"given":"Darren","family":"Cowzer","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne F","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-350X","authenticated-orcid":false,"given":"Henry","family":"Walch","sequence":"additional","affiliation":[{"name":"Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fergus","family":"Keane","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4351-2511","authenticated-orcid":false,"given":"Jinru","family":"Shia","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K G","family":"Do","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman","family":"Yarmohammadi","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P","family":"Erinjeri","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"El Dika","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Yaqubie","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Azhari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Gambarin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Crane","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice C","family":"Wei","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Jarnagin","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Solit","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F","family":"Berger","sequence":"additional","affiliation":[{"name":"Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen M","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[{"name":"Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]},{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-218X","authenticated-orcid":false,"given":"Walid","family":"Chatila","sequence":"additional","affiliation":[{"name":"Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinela","family":"Capanu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghassan K","family":"Abou-Alfa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-4310","authenticated-orcid":false,"given":"James J","family":"Harding","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]},{"name":"Weill Medical College of Cornell University , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"issue":"10088","key":"2024100317300193800_CIT0001","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2024100317300193800_CIT0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024100317300193800_CIT0003","doi-asserted-by":"crossref","first-page":"S1402","DOI":"10.1016\/j.annonc.2022.08.033","article-title":"LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"33","author":"Qin","year":"2022","journal-title":"Ann Oncol"},{"issue":"10408","key":"2024100317300193800_CIT0004","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"The Lancet"},{"issue":"8","key":"2024100317300193800_CIT0005","doi-asserted-by":"crossref","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evidence"},{"issue":"20","key":"2024100317300193800_CIT0006","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"2024100317300193800_CIT0007","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"2024100317300193800_CIT0008","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy\u2014development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"2024100317300193800_CIT0009","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"2024100317300193800_CIT0010","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"Meyer","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"2024100317300193800_CIT0011","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"40","key":"2024100317300193800_CIT0012","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"issue":"3","key":"2024100317300193800_CIT0013","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"2024100317300193800_CIT0014","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00262-020-02743-0","article-title":"An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma","volume":"70","author":"Dai","year":"2021","journal-title":"Cancer Immunol, Immunother: CII"},{"issue":"3","key":"2024100317300193800_CIT0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"7","key":"2024100317300193800_CIT0016","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","article-title":"MSIsensor: microsatellite instability detection using paired tumor-normal sequence data","volume":"30","author":"Niu","year":"2014","journal-title":"Bioinformatics"},{"issue":"2","key":"2024100317300193800_CIT0017","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"1","key":"2024100317300193800_CIT0018","first-page":"PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"7854","key":"2024100317300193800_CIT0019","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"1","key":"2024100317300193800_CIT0020","doi-asserted-by":"crossref","first-page":"733530","DOI":"10.3389\/fimmu.2021.733530","article-title":"Viral status and efficacy of immunotherapy in hepatocellular carcinoma: a systematic review with meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2024100317300193800_CIT0021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-022-00267-7","article-title":"Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade","volume":"6","author":"Yoo","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"8","key":"2024100317300193800_CIT0022","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-catenin activation promotes immune escape and resistance to anti\u2013PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discovery"},{"issue":"10","key":"2024100317300193800_CIT0023","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2024100317300193800_CIT0024","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J Hepatol"},{"issue":"3","key":"2024100317300193800_CIT0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"2024100317300193800_CIT0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2024100317300193800_CIT0027","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1159\/000516490","article-title":"Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma","volume":"10","author":"Vogel","year":"2021","journal-title":"Liver Cancer"},{"issue":"1","key":"2024100317300193800_CIT0028","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/cancers12010182","article-title":"Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"2024100317300193800_CIT0029","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/jgh.13783","article-title":"Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use","volume":"32","author":"Kuo","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"2024100317300193800_CIT0030","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00432-018-2610-z","article-title":"Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study","volume":"144","author":"Abdel-Rahman","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2024100317300193800_CIT0031","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for Child-Pugh Class B advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Xie","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"2024100317300193800_CIT0032","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"2024100317300193800_CIT0033","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.gastro.2023.02.042","article-title":"Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150","volume":"165","author":"Espinoza","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"2024100317300193800_CIT0034","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002\u20132020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"2024100317300193800_CIT0035","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.dld.2023.08.062","article-title":"Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role","volume":"56","author":"Pinto","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"1","key":"2024100317300193800_CIT0036","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"issue":"7559","key":"2024100317300193800_CIT0037","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2024100317300193800_CIT0038","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"issue":"9","key":"2024100317300193800_CIT0039","doi-asserted-by":"crossref","first-page":"e2300140","DOI":"10.1200\/GO.23.00140","article-title":"Biospecimen repositories in low- and middle-income countries: insights from an American University of Beirut and Memorial Sloan Kettering Collaboration","volume":"9","author":"Faraj","year":"2023","journal-title":"JCO Global Oncol"},{"issue":"8","key":"2024100317300193800_CIT0040","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"2024100317300193800_CIT0041","doi-asserted-by":"crossref","first-page":"e001945","DOI":"10.1136\/jitc-2020-001945","article-title":"Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors","volume":"9","author":"Wong","year":"2021","journal-title":"J ImmunoTher Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/894\/59558408\/oyae110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/894\/59558408\/oyae110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T17:35:25Z","timestamp":1727976925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/10\/894\/7700812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,6,27]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae110","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,6,27]]}}}